Market Closed -
Other stock markets
|
After market 02:40:05 pm | |||
90.56 EUR | -1.23% | 90.46 | -0.10% |
May. 14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... | |
May. 14 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.89% | 124B | B+ | ||
+31.37% | 588B | B | ||
-2.79% | 364B | C+ | ||
+20.48% | 326B | B- | ||
+5.49% | 285B | C+ | ||
+14.83% | 239B | B+ | ||
+9.93% | 210B | B- | ||
-6.95% | 200B | A+ | ||
+10.82% | 167B | C+ | ||
+0.14% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi